Page 14 - Nasdaq First News Today

Faron Pharmaceuticals Oy   Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress Bexmarilimab mode of action in AML/MDS supported with durable Clever-1... | June 9, 2023

The Board of Directors of Crown Energy AB has decided to evaluate the conditions for listing the companys share on Nasdaq First North Growth Market, Stockholm. A list change is expected to take... | May 31, 2023

Final result of the subsequent offer period of Montana BidCo's public cash offer to the shareholders of Nordic Lights Group Montana BidCo Oy COMPANY RELEASE May 11, 2023 at 5:00 p.m.

Montana BidCo Oy COMPANY RELEASE May 9, 2023 at 5:00 p.m. EEST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA

Montana BidCo Oy to commence redemption proceedings in respect of the remaining minority shares in Nordic Lights Group Corporation Montana BidCo Oy COMPANY RELEASE May 3, 2023 at 5:00

3.5.2023 17:30:00 EEST | Nordic Lights Group Oyj | Company Announcement Nordic Lights Group Corporation COMPANY RELEASE May 3, 2023 at 5.30 p.m. EEST   NOT FOR RELEASE, PUBLICATION OR... | May 3, 2023

2023-05-03 PRESSRELEASE Arcoma AB has received certification according to MDR (MAR) We are proud to announce that Arcoma AB has received certification...

2023-05-03 PRESSRELEASE Arcoma AB has received certification according to MDR We are proud to announce that Arcoma AB has received certification according to MDR . Arcomas product range of... | May 3, 2023

Investegate announcements from Faron Pharma. Oy, Bexmarilimab Efficacy and Safety in MATINS Trial

<p><span>Nasdaq, Inc. (Nasdaq: NDAQ) today reported financial results for the first quarter of 2023.</span></p>